EP0511285A4 - Vector with multiple target response elements affecting gene expression - Google Patents

Vector with multiple target response elements affecting gene expression

Info

Publication number
EP0511285A4
EP0511285A4 EP19910903122 EP91903122A EP0511285A4 EP 0511285 A4 EP0511285 A4 EP 0511285A4 EP 19910903122 EP19910903122 EP 19910903122 EP 91903122 A EP91903122 A EP 91903122A EP 0511285 A4 EP0511285 A4 EP 0511285A4
Authority
EP
European Patent Office
Prior art keywords
target response
vector
construct
multiple target
response elements
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19910903122
Other languages
French (fr)
Other versions
EP0511285A1 (en
Inventor
Julianna Lisziewicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Commerce
Original Assignee
US Department of Commerce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Commerce filed Critical US Department of Commerce
Publication of EP0511285A1 publication Critical patent/EP0511285A1/en
Publication of EP0511285A4 publication Critical patent/EP0511285A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to viral inhibition, particularly HIV inhibition, by DNA sequences including multiple target response elements. This is the first time that a construct, proposed for gene therapy use, is under the control of a biological regulation. The protective gene product will only be expressed, if the cell becomes infected and a viral protein is made. The DNA construct of the present invention comprises a vector and a promoter operably linked to at least one target response element so that the elements are transcribed in tandem. The DNA construct can be used in the treatment of viral infections, in particular HIV associated diseases, by obtaining cells from an HIV-infected patient, transforming the cells with the construct and administering the transformed cell to the patient.
EP19910903122 1990-01-18 1991-01-16 Vector with multiple target response elements affecting gene expression Withdrawn EP0511285A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US46740790A 1990-01-18 1990-01-18
US467407 1990-01-18
US59629990A 1990-10-15 1990-10-15
US596299 1990-10-15

Publications (2)

Publication Number Publication Date
EP0511285A1 EP0511285A1 (en) 1992-11-04
EP0511285A4 true EP0511285A4 (en) 1993-05-26

Family

ID=27042041

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19910903122 Withdrawn EP0511285A4 (en) 1990-01-18 1991-01-16 Vector with multiple target response elements affecting gene expression

Country Status (6)

Country Link
EP (1) EP0511285A4 (en)
JP (1) JP2746480B2 (en)
KR (1) KR0148782B1 (en)
AU (1) AU642959B2 (en)
CA (1) CA2074188C (en)
WO (1) WO1991010453A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0454781B1 (en) * 1989-01-23 1998-12-16 Chiron Corporation Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof
US5871958A (en) * 1989-05-25 1999-02-16 Duke University Mutant rev genes encoding transdominant repressors of HIV replication
US6251675B1 (en) 1989-05-25 2001-06-26 Duke University Methods utilizing mutant rev genes encoding transdominant repressors of HIV replication
US6245560B1 (en) * 1990-01-18 2001-06-12 The United States Of America As Represented By The Department Of Health And Human Services Vector with multiple target response elements affecting gene expression
GB9125623D0 (en) * 1991-12-02 1992-01-29 Dynal As Cell modification
GB9206874D0 (en) * 1992-03-30 1992-05-13 Connaught Lab Generation of improved inducible mammalian expression vectors
US6469158B1 (en) 1992-05-14 2002-10-22 Ribozyme Pharmaceuticals, Incorporated Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5804683A (en) * 1992-05-14 1998-09-08 Ribozyme Pharmaceuticals, Inc. Deprotection of RNA with alkylamine
US5977343A (en) 1992-05-14 1999-11-02 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5686599A (en) * 1992-05-14 1997-11-11 Ribozyme Pharmaceuticals, Inc. Synthesis, deprotection, analysis and purification of RNA and ribozymes
US5693535A (en) * 1992-05-14 1997-12-02 Ribozyme Pharmaceuticals, Inc. HIV targeted ribozymes
US5654398A (en) * 1993-06-03 1997-08-05 The Regents Of The University Of California Compositions and methods for inhibiting replication of human immunodeficiency virus-1
GB9319772D0 (en) * 1993-09-24 1993-11-10 Therexsys Ltd Therapeutic agent
US5877018A (en) * 1994-10-20 1999-03-02 Connaught Laboratories Limited Synthetic eukaryotic promoters containing two inducible elements
WO1997007808A1 (en) * 1995-08-25 1997-03-06 The Regents Of The University Of California Chimeric antiviral agents which incorporate rev binding nucleic acids
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
SK287538B6 (en) * 1998-03-20 2011-01-04 Commonwealth Scientific And Industrial Research Organisation Control of gene expression
AU9196798A (en) * 1998-05-04 1999-11-23 Julianna Lisziewicz Chimeric decoy rnas having synergistic anti-hiv activity
US6399067B1 (en) 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
AU2006214563B2 (en) 2005-02-15 2011-08-18 Thymon, L.L.C. Methods and compositions for impairing multiplication of HIV-1
IT1397569B1 (en) 2009-12-10 2013-01-16 Icgeb PEPTIDES AND THEIR DERIVATIVES THAT INHIBIT THE EXTRACELLULAR RELEASE OF HIV-1 PROTEIN TAT AND THE REPLICATION OF HIV-1.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOLOGICAL ABSTRACTS vol. 91, no. 9 , May 1991, Philadelphia, PA, US; abstract no. 95237, LISZIEWICZ, J. ET AL. 'Tat-regulated production of multimerized TAR RNA inhibits HIV-1 gene expression' page 392 ; *
See also references of WO9110453A1 *

Also Published As

Publication number Publication date
AU642959B2 (en) 1993-11-04
EP0511285A1 (en) 1992-11-04
WO1991010453A1 (en) 1991-07-25
CA2074188A1 (en) 1991-07-19
JPH05504255A (en) 1993-07-08
KR920703118A (en) 1992-12-17
JP2746480B2 (en) 1998-05-06
AU7074091A (en) 1991-08-05
KR0148782B1 (en) 1998-08-17
CA2074188C (en) 2004-05-11

Similar Documents

Publication Publication Date Title
EP0511285A4 (en) Vector with multiple target response elements affecting gene expression
JP2515308B2 (en) Human immune interferon
Arazi et al. Production of antiviral and antitumor proteins MAP30 and GAP31 in cucurbits using the plant virus vector ZYMV-AGII
EP0400958A3 (en) Live vaccines
AU2790292A (en) Viral recombinant vectors for expression in muscle cells
IE842193L (en) Plasmid with tandem promoter system
EP0340109A3 (en) Anti-t-cell receptor determinants as autoimmune disease treatment
WO1995000638A3 (en) Antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection
WO1992001049A3 (en) Cd53 cell surface antigen and use thereof
DK0662157T3 (en) Preparations and Methods for the Treatment of Hepatitis C Virus-Associated Diseases
KR19980064289A (en) Pharmacologically Controlled Self Enhancing Expression System
CA2130360A1 (en) Sulfonic Acid Derivatives in the Treatment of Viral Diseases
EP1939290A3 (en) Gene expression control
Vilček et al. Superinduction of interferon with metabolic inhibitors: possible mechanisms and practical applications
CA2215328A1 (en) Novel human cytomegalovirus dna sequences
WO1995003406A3 (en) Enhancement of oligonucleotide inhibition of protein production, cell proliferation, and/or multiplication of infectious disease pathogens
ES2240971T3 (en) TUMOR SUPPRESSING GENES, PROTEINS CODED BY THEM AND USE OF SUCH GENES AND PROTEINS.
WO1996031607A3 (en) Use of an 'immunodeficiency-virus suppressing lymphokine (isl)' to inhibit the replication of viruses, in particular of retroviruses
JPS5519239A (en) Interferon-producing attractant
CN102821783B (en) Treatment HIV infects and the related indication fusion of AIDS and method
Lohrengel et al. Expression and purification of woodchuck tumour necrosis factor alpha
KR950701345A (en) Novel peptide having elastase inhibitory activity and method for producing the same
Weil et al. Interferon induction of (2′–5′) oligoisoadenylate synthetase in diploid and trisomy 21 human fibroblasts: Relation to dosage of the interferon receptor gene (IRFC)
Bausek et al. Two mechanisms of cell resistance to repeated stimulation of interferon
Stevens Transcripts associated with herpes simplex virus latency

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19920724

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19930405

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19941103

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 12N 15/86 A, 7C 12N 15/63 B, 7A 61K 48/00 B, 7C 12N 9/00 B

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 12N 15/86 A, 7C 12N 15/63 B, 7A 61K 48/00 B, 7C 12N 9/00 B

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20011030